Bioactive Products
| A unique collection of 50 Anti-Atherosclerotic natural compounds for Anti-Atherosclerotic research | ||
| Catalog No: | Bb133 | Anti-Atherosclerotic Compound Library Screening Details |
| Size: | 1mg/well * 50 Compounds 2mg/well * 50 Compounds | |
| Cat. No. | Information |
| CFN98147 | Harpagoside Harpagoside has anti-inflammatory effects, it blocks lipopolysaccharide (LPS)-induced bone loss in an inflammatory osteoporosis model, and it does not prevent ovariectomy-mediated bone erosion in a postmenopausal osteoporosis model, it may lead to a partial prevention of obesity-induced atherosclerosis by attenuating inflammatory responses. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-κB activation. Harpagoside exerts neuroprotection effect and ameliorates learning and memory deficit appears to be associated, at least in part, with up-regulation of brain-derived neurotrophic factor (BDNF) content as well as activating its downstream signaling pathways, e.g., MAPK/PI3K pathways. |
| CFN98337 | Geniposidic acid Geniposidic acid is an effective anticancer and radioprotection agent, used to treat inflammation, jaundice and hepatic disorders. It has anti-atherosclerotic effects, can protect vascular endothelium and reverse plaque formation in an atherosclerotic model. Geniposidic acid has effects on the expression of MRP2 and BSEP in BRL-3A cells after FXR gene silencing mediated by si RNA. |
| CFN98440 | Alpinumisoflavone Alpinumisoflavone has atheroprotective effects, may result from their ability to upregulate mechanisms promoting HDL-cholesterol and bile acid formation, it is endowed with estrogenic properties accounting, at least in part, for E. lysistemon effects. Alpinumisoflavone induces cell death, may be via repressing both the ERK/MAPK and NF-κB pathways. Alpinumisoflavone is active against both Gram-negative and Gram-positive bacteria, the minimum inhibitory concentration values obtained (MIC) ranged from 3.9 ug/mL to 125 ug/mL. |
| CFN98519 | Buddlejasaponin IV Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation. Buddlejasaponin IV exerts cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes, it may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat. |
| CFN98478 | Cryptotanshinone Cryptotanshinone is a potent STAT3 inhibitor with IC50 of 4.6 μM, and inhibits STAT3 Tyr705 phosphorylation in DU145 prostate cancer cells. It is also an AR inhibitor to suppress androgen/AR-mediated cell growth and PSA expression by blocking AR dimerization and the AR-coregulator complex formation. Cryptotanshinone has anti-atherosclerosis, neuroprotective, anti-cancer,and anti-neointimal formation activities. Cryptotanshinone reverses DEX-induced androgen excess and ovarian IR in mice through activation of insulin signaling and the regulation of glucose transporters and hormone-synthesizing enzymes, it has an inhibitory effect on MMP-9 production and migration of human aortic smooth muscle cells treated with TNF-alpha in a dose-dependent manner. |
